ICD-10-CM Code C53.9

Malignant neoplasm of cervix uteri, unspecified

Version 2020 Billable Code Diagnoses For Females Only Neoplasm Malignant Primary

Valid for Submission

C53.9 is a billable code used to specify a medical diagnosis of malignant neoplasm of cervix uteri, unspecified. The code is valid for the year 2020 for the submission of HIPAA-covered transactions. The ICD-10-CM code C53.9 might also be used to specify conditions or terms like adenocarcinoma of cervix, adenoid basal carcinoma of cervix uteri, adenoid cystic carcinoma of cervix uteri, adenoma malignum, adenosarcoma of cervix uteri, adenosarcoma of uterus, etc

The code C53.9 is applicable to female patients only. It is clinically and virtually impossible to use this code on a non-female patient.

The following anatomical sites found in the Table of Neoplasms apply to this code given the correct histological behavior: cervix (cervical) (uteri) (uterus) or uterus, uteri, uterine cervix .

ICD-10:C53.9
Short Description:Malignant neoplasm of cervix uteri, unspecified
Long Description:Malignant neoplasm of cervix uteri, unspecified

Index to Diseases and Injuries

The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10 code(s). The following references for the code C53.9 are found in the index:


Code Edits

The Medicare Code Editor (MCE) detects and reports errors in the coding of claims data. The following ICD-10 Code Edits are applicable to this code:

  • Diagnoses for females only - Medicare Code Editor detects inconsistencies between a patient’s sex and any diagnosis on the patient’s record, this code applies to FEMALES only .

Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • Adenocarcinoma of cervix
  • Adenoid basal carcinoma of cervix uteri
  • Adenoid cystic carcinoma of cervix uteri
  • Adenoma malignum
  • Adenosarcoma of cervix uteri
  • Adenosarcoma of uterus
  • Adenosquamous carcinoma of cervix
  • Adenosquamous cell carcinoma
  • Carcinoma of cervix
  • Carcinoma of uterine cervix, invasive
  • Carcinosarcoma of cervix uteri
  • Carcinosarcoma of uterus
  • FIGO CC stage I
  • FIGO CC stage IA1
  • FIGO CC stage IA2
  • FIGO CC stage Ib occ
  • FIGO CC stage IB1
  • FIGO CC stage IB2
  • FIGO CC stage II
  • FIGO CC stage IIA1
  • FIGO CC stage IIA2
  • FIGO CC stage IIB
  • FIGO CC stage III
  • FIGO CC stage IIIA
  • FIGO CC stage IIIB
  • FIGO CC stage IV
  • FIGO CC stage IVA
  • FIGO CC stage IVB
  • Glassy cell carcinoma of cervix uteri
  • International Federation of Gynecology and Obstetrics cervical cancer stage Ia
  • International Federation of Gynecology and Obstetrics cervical cancer stage Ib
  • Invasive carcinoma of uterine cervix co-occurrent with human immunodeficiency virus infection
  • Leiomyosarcoma of cervix uteri
  • Leiomyosarcoma of uterus
  • Local recurrence of malignant tumor of cervix
  • Malignant germ cell neoplasm of cervix uteri
  • Malignant neoplasm of endocervical canal
  • Malignant neoplastic disease co-occurrent with human immunodeficiency virus infection
  • Malignant tumor involving an organ by direct extension from uterine cervix
  • Malignant tumor involving an organ by separate metastasis from uterine cervix
  • Malignant tumor involving bladder by direct extension from uterine cervix
  • Malignant tumor involving bladder by separate metastasis from uterine cervix
  • Malignant tumor involving left fallopian tube by direct extension from uterine cervix
  • Malignant tumor involving left fallopian tube by separate metastasis from uterine cervix
  • Malignant tumor involving left ovary by direct extension from uterine cervix
  • Malignant tumor involving left ovary by separate metastasis from uterine cervix
  • Malignant tumor involving rectum by direct extension from uterine cervix
  • Malignant tumor involving rectum by separate metastasis from uterine cervix
  • Malignant tumor involving right fallopian tube by direct extension from uterine cervix
  • Malignant tumor involving right fallopian tube by separate metastasis from uterine cervix
  • Malignant tumor involving right ovary by direct extension from uterine cervix
  • Malignant tumor involving right ovary by separate metastasis from uterine cervix
  • Malignant tumor involving uterine corpus by direct extension from uterine cervix
  • Malignant tumor involving uterine corpus by separate metastasis from uterine cervix
  • Malignant tumor involving vagina by direct extension from uterine cervix
  • Malignant tumor involving vagina by separate metastasis from uterine cervix
  • Malignant tumor involving vulva by direct extension from uterine cervix
  • Malignant tumor involving vulva by separate metastasis from uterine cervix
  • Malignant tumor of cervix
  • Metastasis from malignant tumor of cervix
  • pM1
  • Primary adenocarcinoma of cervix uteri
  • Primary malignant neoplasm of uterine cervix
  • Primitive neuroectodermal tumor
  • Primitive neuroectodermal tumor of cervix uteri
  • pT1
  • pT1a
  • pT1a1
  • pT1a1 category
  • pT1a2
  • pT1a2 category
  • pT1b
  • pT1b1
  • pT1b1 category
  • pT1b2
  • pT1b2 category
  • pT2
  • pT2a
  • pT2b
  • pT3
  • pT3a
  • pT3b
  • pT4
  • Rhabdomyosarcoma of cervix uteri
  • Secondary malignant neoplasm of body of uterus
  • Secondary malignant neoplasm of left fallopian tube
  • Secondary malignant neoplasm of left ovary
  • Secondary malignant neoplasm of rectum
  • Secondary malignant neoplasm of right fallopian tube
  • Secondary malignant neoplasm of right ovary
  • Secondary malignant neoplasm of vagina
  • Secondary malignant neoplasm of vulva
  • Squamous cell carcinoma of cervix
  • T1 : Cervical carcinoma confined to uterus
  • T1a : Invasive carcinoma of uterine cervix diagnosed by microscopy only
  • T1a1 : Tumor of uterine cervix with stromal invasion < 3.0 mm in depth and horizontal spread < 7.0 mm
  • T1a2 : Tumor of uterine cervix with stromal invasion > 3.0 mm but < 5.0 mm in depth and horizontal spread < 7.0 mm
  • T1b : Tumor of uterine cervix with clinically visible lesion confined to the cervix or microscopic lesion greater than T1a2/IA2
  • T1b1 : Tumor of uterine cervix, clinically visible lesion < 4.0 mm in greatest dimension
  • T1b2 : Tumor of uterine cervix, clinically visible lesion > 4.0 mm in greatest dimension
  • T2 : Tumor of uterine cervix invades beyond the uterus but not to pelvic wall or to lower third of vagina
  • T2a : Tumor of uterine cervix, T2 without parametrial invasion
  • T2b : Tumor of uterine cervix, T2 with parametrial invasion
  • T3 : Tumor of uterine cervix extends to the pelvic wall and/or involves the lower third of the vagina and/or causes hydronephrosis or nonfunctioning kidney
  • T3a : Tumor of uterine cervix involves lower third of vagina, but not pelvic wall
  • T3b : Tumor of uterine cervix extends to pelvic wall and/or causes hydronephrosis or nonfunctioning kidney
  • T4 : Tumor of uterine cervix/vagina invades mucosa of bladder or rectum and/or extends beyond true pelvis

Diagnostic Related Groups

The ICD-10 code C53.9 is grouped in the following groups for version MS-DRG V37.0 What are Diagnostic Related Groups?
The Diagnostic Related Groups (DRGs) are a patient classification scheme which provides a means of relating the type of patients a hospital treats. The DRGs divides all possible principal diagnoses into mutually exclusive principal diagnosis areas referred to as Major Diagnostic Categories (MDC).
applicable from 10/01/2019 through 09/30/2020.

  • 736 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH MCC
  • 737 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITH CC
  • 738 - UTERINE AND ADNEXA PROCEDURES FOR OVARIAN OR ADNEXAL MALIGNANCY WITHOUT CC/MCC
  • 739 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH MCC
  • 740 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITH CC
  • 741 - UTERINE, ADNEXA PROCEDURES FOR NON-OVARIAN AND NON-ADNEXAL MALIGNANCY WITHOUT CC/MCC

Convert C53.9 to ICD-9

  • 180.9 - Mal neo cervix uteri NOS

Code Classification

  • Neoplasms (C00–D48)
    • Malignant neoplasms of female genital organs (C51-C58)
      • Malignant neoplasm of cervix uteri (C53)

Code History

  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016
    (First year ICD-10-CM implemented into the HIPAA code set)
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020

Table of Neoplasms

The code C53.9 is included in the table of neoplasms by anatomical site. For each site there are six possible code numbers according to whether the neoplasm in question is malignant, benign, in situ, of uncertain behavior, or of unspecified nature. The description of the neoplasm will often indicate which of the six columns is appropriate.

Where such descriptors are not present, the remainder of the Index should be consulted where guidance is given to the appropriate column for each morphological (histological) variety listed. However, the guidance in the Index can be overridden if one of the descriptors mentioned above is present.

Neoplasm, neoplastic Malignant
Primary
Malignant
Secondary
CaInSitu Benign Uncertain
Behavior
Unspecified
Behavior
»cervix (cervical) (uteri) (uterus)
C53.9C79.82D06.9D26.0D39.0D49.59
»uterus, uteri, uterine
  »cervix
C53.9C79.82D06.9D26.0D39.0D49.59

Information for Patients


Cervical Cancer

The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cervical cancer is caused by a virus called HPV. The virus spreads through sexual contact. Most women's bodies are able to fight HPV infection. But sometimes the virus leads to cancer. You're at higher risk if you smoke, have had many children, use birth control pills for a long time, or have HIV infection.

Cervical cancer may not cause any symptoms at first. Later, you may have pelvic pain or bleeding from the vagina. It usually takes several years for normal cells in the cervix to turn into cancer cells. Your health care provider can find abnormal cells by doing a Pap test to examine cells from the cervix. You may also have an HPV test. If your results are abnormal, you may need a biopsy or other tests. By getting regular screenings, you can find and treat any problems before they turn into cancer.

Treatment may include surgery, radiation therapy, chemotherapy, or a combination. The choice of treatment depends on the size of the tumor, whether the cancer has spread and whether you would like to become pregnant someday.

Vaccines can protect against several types of HPV, including some that can cause cancer.

NIH: National Cancer Institute


[Learn More]